State Of Wyoming I Teos Therapeutics, Inc. Transaction History

State Of Wyoming

$676 Million
Q3 2024

A detailed history of State Of Wyoming transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, State Of Wyoming holds 3,320 shares of ITOS stock, worth $23,970. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,320

Holding current value

$23,970

% of portfolio

0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$10.09 - $17.97 $33,498 - $59,660	3,320 New	3,320 $33,000
Q1 2023 May 12, 2023	BUY	$13.02 - $22.62 $19,920 - $34,608	1,530 Added 33.8%	6,056 $82,000
Q4 2022 Feb 14, 2023	BUY	$17.77 - $21.6 $2,683 - $3,261	151 Added 3.45%	4,526 $88,000
Q3 2022 Nov 14, 2022	BUY	$18.6 - $27.25 $68,001 - $99,626	3,656 Added 508.48%	4,375 $83,000
Q2 2022 Aug 15, 2022	BUY	$16.57 - $35.1 $11,748 - $24,885	709 Added 7090.0%	719 $15,000
Q1 2022 May 13, 2022	BUY	$31.92 - $47.45 $63 - $94	2 Added 25.0%	10 $0
Q4 2021 Feb 11, 2022	SELL	$26.23 - $47.86 $26 - $47	-1 Reduced 11.11%	8 $0
Q3 2021 Feb 11, 2022	SELL	$23.91 - $29.58 $95 - $118	-4 Reduced 30.77%	9 $0
Q2 2021 Feb 11, 2022	BUY	$17.9 - $36.1 $125 - $252	7 Added 116.67%	13 $0
Q1 2021 Feb 08, 2022	BUY	$30.86 - $44.2 $185 - $265	6 New	6 $0

Others Institutions Holding ITOS

# of Institutions

166

Shares Held

36.6M

Call Options Held

1.95M

Put Options Held

374K

Black Rock Inc. New York, NY

3.73M
Shares

$26.9 Million
0.0% of portfolio
Ra Capital Management, L.P. Boston, MA

3.18M
Shares

$23 Million
0.45% of portfolio
Boxer Capital, LLC San Diego, CA

2.95M
Shares

$21.3 Million
1.6% of portfolio
Mpm Asset Management LLC Cambridge, MA

2.74M
Shares

$19.8 Million
19.24% of portfolio
Tang Capital Management LLC San Diego, CA

2.41M
Shares

$17.4 Million
2.09% of portfolio

View Full List

About iTeos Therapeutics, Inc.

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $257M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

More about ITOS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Wyoming, based on Form 13F filings with the SEC.

News

Stay updated on State Of Wyoming with notifications on news.

Account